Outpace Bio
Marc Lajoie has a diverse work experience in the biotechnology and research fields. Marc is currently the co-founder and Chief Executive Officer of Outpace Bio, a position they have held since November 2020. Prior to this, they were a co-founder and advisor at GRO Biosciences starting from August 2016. From January 2019 to November 2020, they served as a co-founder and Senior Director of Protein & Cell Engineering at Lyell Immunopharma. Before transitioning to industry, Marc held research positions at the University of Washington, where they were a Washington Research Foundation Innovation Postdoctoral Fellow and Cancer Research Institute Fellow from September 2014 to December 2018. Marc also worked as a Graduate Student at Harvard Medical School in the George M. Church Lab from January 2009 to August 2014.
Marc Lajoie began their education in 2004 at Dartmouth College, where they pursued a Bachelor of Arts degree in Biophysical Chemistry. Marc completed their undergraduate studies in 2008. Following this, they enrolled at Harvard University in 2008, where they embarked on a Ph.D program in the Chemical Biology Program. Marc Lajoie completed their Ph.D at Harvard University in 2013.
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.It offers a platform that combines custom-designed biological functions with cellular control modalities that program the right response at the right time and place. It creates a mechanism-driven solution tailor-made to improve efficacyand safety. The company collaborates with Lyell Immunopharma to develop and commercialize a potential immune cell therapy for the treatment of cancer, auto-immune diseases, infectious diseases, degenerative diseases, regenerative medicine, metabolic disorders, and genetic disorders, enabling healthcare providers to cure a wide range of diseases as per patient's need.